Evaluation of Neoadjuvant Chemotherapy Effect in Osteosarcoma.
10.5292/jkbjts.2014.20.2.66
- Author:
Min Wook JOO
1
;
Yong Koo KANG
;
Ie Ryung YOO
;
Woo Hee CHOI
;
Yang Guk CHUNG
;
Dong Hyun KIM
;
Jin Woo KANG
Author Information
1. Department of Orthopaedic Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. ygchung@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
osteosarcoma;
neoadjuvant therapy;
necrosis;
positron-emission tomography
- MeSH:
Diagnostic Imaging;
Drug Therapy*;
Female;
Humans;
Joints;
Male;
Necrosis;
Neoadjuvant Therapy;
Osteosarcoma*;
Positron-Emission Tomography;
Positron-Emission Tomography and Computed Tomography;
Tumor Burden
- From:The Journal of the Korean Bone and Joint Tumor Society
2014;20(2):66-73
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Various diagnostic imaging modalities have been used to evaluate the effect of neoadjuvant chemotherapy for osteosarcoma early and noninvasively. We evaluated the effectiveness of imaging studies of plain radiographs and positron-emission tomography/computed tomography (PET/CT) in predicting neoadjuvant chemotherapy effect for osteosarcoma and tried to establish a general principle in interpretation of PET/CT parameters. MATERIALS AND METHODS: Eighteen patients who underwent two cycles of neoadjuvant chemotherapy and surgical excision for osteosarcoma were enrolled. There were 13 males and 5 females, with a median age of 19 (11-63) years. Fifteen patients of 18 had the American Joint Committe on Cancer (AJCC) stage IIB. They had plain radiographs and PET/CT before and after neoadjuvant chemotherapy. The resected tumor specimens were pathologically examined to determine histological response grade using a conventional mapping method. Statistical analysis was performed to evaluate the correlation between histopathological necrosis rate, and radiographic finding category, post-chemotherapy maximum standardized uptake value (SUVmax), average standardized uptake value and metabolic tumor volume (MTV) as well as reduction rates of them. RESULTS: Eight patients were good responders to neoadjuvant chemotherapy based on histological evaluation. Median SUVmax reduction rate was 73 (23-77) % in good responders and 42 (-32-76) % in poor responders. Median MTV reduction rate was 93.5 (62-99) % in good responders and 46 (-81-100) % in poor responders. While radiographic finding category was not different according to histological response (p=1.0), SUVmax reduction rate was significantly different (p=0.041). Difference in MTV reduction rates approached statistical significance as well (p=0.071). CONCLUSION: While radiographic finding category was not reliable to assess neoadjuvant chemotherapy effect for osteosarcoma, reduction rate of SUVmax was a useful indicator in this study. As parameters of PET/CT can be influenced by various factors of settings, different centers have to make an effort to establish their own standard of judgement with reference of previous studies.
